10390 Pacific Center Court
United States - Map
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic vaccine for herpes simplex virus type 2, which is under Phase 1/2 clinical trial to prevent and protect against recurring flare-ups, reduce viral shedding, and transmission. The company, through corporate collaborations, is also developing ASP0113, which is under Phase III clinical trial for prevention of CMV reactivation in stem cell transplant recipients, as well as in Phase II clinical trial for prevention of CMV infection in kidney transplant recipients; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to enhance survival time of dogs with oral melanoma. In addition, Vical Incorporated, through government collaboration, is developing Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all four dengue serotypes. Further, it engages in contract manufacturing of plasmid investigational products for various clients. The company was founded in 1987 and is headquartered in San Diego, California.
|Vical Incorporated’s ISS Governance QuickScore as of Jul 1, 2014 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 10; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Vijay B. Samant ,
Chief Exec. Officer, Pres, Acting Chief Financial Officer and Director
|Mr. Anthony Alan Ramos ,
Chief Accounting Officer and VP of Fin.
|Dr. Igor P. Bilinsky Ph.D.,
Sr. VP of Corp. Devel.
|Dr. Lawrence Russell Smith Ph.D.,
VP of Vaccine Research
|Dr. Mammen P. Mammen Jr., M.D.,
VP of Clinical Vaccines
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|